Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of Capricor Therapeutics Inc (NASDAQ: CAPR) was $12.83 for the day, down -1.53% from the previous closing price of $13.03. In other words, the price has decreased by $-1.53 from its previous closing price. On the day, 0.93 million shares were traded. CAPR stock price reached its highest trading level at $13.42 during the session, while it also had its lowest trading level at $12.63.
Ratios:
Our analysis of CAPR’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 7.77 and its Current Ratio is at 7.77. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Piper Sandler on October 21, 2024, initiated with a Overweight rating and assigned the stock a target price of $35.
On May 17, 2024, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $14.
On January 05, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $8.Cantor Fitzgerald initiated its Overweight rating on January 05, 2024, with a $8 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 20 ’24 when Nippon Shinyaku Co Ltd bought 2,798,507 shares for $5.36 per share. The transaction valued at 14,999,998 led to the insider holds 7,090,351 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CAPR now has a Market Capitalization of 606589568 and an Enterprise Value of 435960896. For the stock, the TTM Price-to-Sale (P/S) ratio is 26.31 while its Price-to-Book (P/B) ratio in mrq is 4.02. Its current Enterprise Value per Revenue stands at 19.576 whereas that against EBITDA is -10.597.
Stock Price History:
The Beta on a monthly basis for CAPR is 0.83, which has changed by 1.434535 over the last 52 weeks, in comparison to a change of 0.097913146 over the same period for the S&P500. Over the past 52 weeks, CAPR has reached a high of $23.40, while it has fallen to a 52-week low of $3.52. The 50-Day Moving Average of the stock is 3.65%, while the 200-Day Moving Average is calculated to be 5.21%.
Shares Statistics:
CAPR traded an average of 1.36M shares per day over the past three months and 1416060 shares per day over the past ten days. A total of 45.58M shares are outstanding, with a floating share count of 40.12M. Insiders hold about 12.16% of the company’s shares, while institutions hold 39.02% stake in the company. Shares short for CAPR as of 1744675200 were 10671483 with a Short Ratio of 7.83, compared to 1741910400 on 9072729. Therefore, it implies a Short% of Shares Outstanding of 10671483 and a Short% of Float of 26.58.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current rating of Capricor Therapeutics Inc (CAPR) reflects the combined expertise of 5.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $-0.32, with high estimates of $-0.18 and low estimates of $-0.4.
Analysts are recommending an EPS of between $1.63 and $-1.39 for the fiscal current year, implying an average EPS of $-0.24. EPS for the following year is $-0.07, with 5.0 analysts recommending between $1.37 and $-1.28.
Revenue Estimates
Based on 7 analysts’ estimates, the company’s revenue will be $108.19M in the next fiscal year. The high estimate is $259.35M and the low estimate is $40M.
